Evaluating Long-Term Outcomes and Personalized Treatment Strategies in Advanced Gastrointestinal Cancers
Panelists discuss how the long-term follow-up data from CheckMate649 are crucial for understanding the durability of nivolumab plus chemotherapy’s benefit in first-line advanced gastric cancers (GCs)/gastroesophageal junction cancers (GEJCs). The survival outcomes help validate this regimen’s position as a standard of care, particularly for patients with PD-L1 combined positive score (CPS) ≥ 5. Although the magnitude of benefit varies by PD-L1 expression, both overall survival (OS) and progression-free survival (PFS) data inform personalized treatment decisions, with stronger evidence supporting immunotherapy use in higher PD-L1–expressing tumors while maintaining use across most patient subgroups.
EP: 1.Treatment Landscape and Unmet Needs in Advanced Gastric Cancers
EP: 2.CheckMate649 5-Year Follow-Up, Study Design, and Efficacy Results
EP: 3.Evaluating Long-Term Outcomes and Personalized Treatment Strategies in Advanced Gastrointestinal Cancers
EP: 4.Assessing the Long-Term Safety and Efficacy of Nivolumab Plus Chemotherapy for Broader Clinical Adoption in Advanced GI Cancers
EP: 5.Balancing Treatment Intensity, Quality of Life, and Biomarker-Driven Approaches in Advanced GI Cancers
EP: 6.Advancing First-Line Treatment Strategies in Gastric and Esophageal Cancers
EP: 7.Key Takeaways and Future in Advanced Gastric Cancer Treatment
EP: 8.Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
- Please comment on the significance of a 5-year update for CheckMate649.
- How might this affect your current clinical practice?
- How do the OS and PFS benefits at 5 years reinforce or challenge nivolumab plus chemotherapy as the standard first-line treatment for this patient population?
- How might the OS benefit in subgroups, particularly those defined by PD-L1 CPS thresholds, guide personalized treatment strategies for advanced GC/GEJC/esophageal adenocarcinoma?
- How might these results influence treatment decisions for patients with low vs high PD-L1 CPSs?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
